• China Traditional Chinese Medicine Holdings expects a net loss of RMB 800 million to RMB 850 million for the six months ended June 30, 2026.
• The prior-year loss for the same period was RMB 141.76 million.
• Concentrated TCM granules revenue, margins weakened amid policy shifts, market changes; further goodwill impairment flagged as a key driver.
• Lower revenue scale, profitability in TCM finished drugs, Chinese medicinal herbs integration; higher asset, credit impairments, remedial taxes also weighed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. China Traditional Chinese Medicine Holdings Co. Limited published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260717-12248764), on July 17, 2026, and is solely responsible for the information contained therein.